Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Total Current Liabilities data on file, last reported at $74.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 47.32% year-over-year to $74.6 million in Q1 2026; TTM through Mar 2026 was $74.6 million, a 47.32% decrease from a year earlier, with the FY2025 full-year figure at $96.9 million, down 46.76% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $74.6 million, down from $96.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for BEAM reached as high as $238.9 million in Q3 2022 and fell as low as $74.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $184.2 million across 5 years, with a median of $187.2 million in 2024.
• Across the five-year window, Total Current Liabilities soared 135.58% in 2022 and slumped 47.32% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $223.6 million in 2022, then slipped by 8.06% to $205.6 million in 2023, then decreased by 11.43% to $182.1 million in 2024, then plunged by 46.76% to $96.9 million in 2025, then decreased by 23.08% to $74.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $74.6 million in Q1 2026, $96.9 million in Q4 2025, and $182.6 million in Q3 2025.